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Abstract 
Anaplastic lymphoma kinase rearranged non-small-cell lung cancer is a rare disease. Among them, a subset of patients exist who 
exhibit relatively slowly progressing symptoms and have oligo-metastases. In this article, we present two cases of ALK rearran-
ged lung adenocarcinoma in patients who experienced postoperative oligo-recurrence. Both cases were treated with surgical 
resection and gamma knife irradiation for oligo-recurrence. After local therapy, the first patient remained disease free for over 
23 months; the second for over 18 months. It appears that some patients with ALK rearranged NSCLC experience oligo-recurrence 
in their clinical course. For such patients, appropriate local therapy may be beneficial in improving both the quality of life and the 
prognosis. 
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Introduction
In non-small-cell lung cancer (NSCLC), the 
understanding of the carcinogenic mechanism 
has progressed. In more than half of NSCLC 
patients, driver gene mutations have received 
increasingly more interest as the causative factor 
in the pathogenesis of this disease [1]. For them, 
it is now possible to administer drugs that can be 
expected to have a specific effect. ALK rearranged 
NSCLC is one type of NSCLC with known driver 
mutation genes, and it accounts for a small per-
centage of NSCLC patients [1]. However, even in 
the presence of drugs with effective specificity, 
the majority of patients who achieved good re-
sponses will still become victims of progressive 
disease. In particular, the prognosis for patients 
suffering from lung cancer with distant metastasis 
remains poor. Progress free survival time varies 
among patients and is unpredictable. Similarly, 
the sites of recurrence are also unpredictable at 
this time.
In this article, we report on two patients 
with solitary small metastatic lesions as a po-
stoperative recurrence where local therapies 
were available. Both patients did not have rapid 
progress thereafter. The presence of ALK rearran-
ged NSCLC patients who showed such unusual 
clinical courses is considered to be notable.
Material and methods
Case 1
A 43-year-old man was noted to have an 
abnormal opacity in chest radiograph during 
mass-screening. Chest CT scan revealed a nodule 
in the lower lobe of the right lung (Figure 1A). Hi-
lar and mediastinal lymph node adenopathy was 
not observed. He was referred to our hospital for 
further examination and treatment. Physical exa-
mination and laboratory data were unremarkable. 
Right lower lobectomy with nodal dissection was 
performed, and the final pathological diagnosis 
was adenocarcinoma. Pathological tumor stage 
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was proven to be T1aN0M0. Fluorescence in situ 
hybridization of the resected specimen revealed 
an ALK translocation. Thereafter, he was followed 
up at our outpatient department without any 
additional adjuvant therapy. Thirty-four months 
after the surgery, follow up chest CT scan reve-
aled 4 new nodules up to 10mm in size in the left 
lung. Two of them were detected in left S6, and 
the others were in left S5 and S8 (Figure 1B). The 
patient had no symptoms and his PS was zero at 
this time. Brain MRI, bone scan and CT of the 
abdomen showed no other distant metastasis. 
These 4 nodules in the left lung were surgically 
removed, and 2 of them in left S6 were patholo-
gically confirmed to be metastatic lesions. He is 
still alive and well with no evidence of recurrence 
in PET/CT and brain MRI 23 months after the 
surgical resection of the oligo-recurrence.
Case 2
A  39-year-old man was admitted to our 
hospital due to an abnormal opacity in chest 
radiograph during mass-screening. Chest CT 
scan revealed a nodule in the lower lobe of the 
left lung (Figure 2A). Hilar and mediastinal 
lymph node adenopathy was not observed. He 
was referred to our division for further exami-
nation and treatment. Physical examination 
and laboratory data were unremarkable. Left 
pneumonectomy with nodal dissection was 
performed, and the final pathological diagnosis 
was adenocarcinoma. Pathological tumor stage 
was proven to be T1bN2M0. Fluorescence in 
situ hybridization of the resected specimen 
revealed an ALK translocation. He received 6 
courses of adjuvant chemotherapy with cispla-
tin, pemetrexed and bevacizumab. Thereafter, 
the patient received maintenance chemotherapy 
with pemetrexed and bevacizumab. PET/CT scan 
taken 17 months after the pneumonectomy re-
vealed a small nodule of the left adrenal grand. 
Morphological appearance and SUVmax value 
suggested adenoma of the adrenal gland. After 
follow up at our outpatient department, the 
nodule did not receive any additional adjuvant 
therapy. Twenty-four months after the pneumo-
nectomy, three small nodules up to 10mm in dia-
meter were detected in a brain MRI (Figure 2B), 
which were treated with gamma knife. At the 
same time, the nodule of the left adrenal gland 
became enlarged with high FDG-uptake on 
PET/CT (Figure 2C), and it was resected sur-
gically 27 months after the pneumonectomy. 
Pathologically, the nodule was confirmed to 
be a metastatic lesion. The patient started to 
receive crizotinib after the local therapies and 
is still alive and well with no evidence of re-
currence in PET/CT and brain MRI 18 months 
after the surgical resection of the adrenal oligo-
-recurrence.
Discussion
ALK rearranged NSCLC accounts for 2–5% of 
all the different varieties of NSCLC, with adeno-
carcinoma being the most common histological 
type [2]. The response period is fairly long due 
to the specific effect of ALK-TKI, but almost all of 
the patients eventually experience recurrence. In 
this report, we identified and examined 2 patients 
Figure 1. A. Chest CT scan of case 1 at the first visit, which showed a nodule in the right lower lobe. B. Chest CT scan of case 1 taken at 34 months 
after the right lower lobectomy. Two nodules detected in left S6 (arrows) were confirmed as metastatic lesions pathologically
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Figure 2. A. Chest CT scan of case 2 at the first visit, which showed a nodule in the left lower lobe. B. Brain MRI of case 2 taken at 24 months 
after the pneumonectomy. Three small nodules up to 10mm in diameter were detected (arrows) and treated with gamma knife. C. FDG-PET/CT 
of case 2 taken at 24 months after the pneumonectomy. A nodule with high FDG-uptake (arrow head) was detected in the left adrenal gland and 
resected surgically
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who presented oligo-recurrence during their long 
clinical courses, which were treated surgically or 
radiologically.
More than 20 years ago, Wechselbaum and 
Hellman proposed the term “oligometastases” [3], 
and thereafter, Niibe et al. proposed the concept 
of “oligo-recurrence” [4, 5]. According to them, 
oligometastases was defined as between one and 
several distant metastases/recurrences in one to 
several organs that can be treated by local therapy 
[3]. However, the patients who had oligometasta-
ses with an uncontrolled primary site suffered 
from treatment failure. The most important pro-
gnostic factor for oligometastases is the status of 
the primary site [4–6]. Niibe et al. proposed the 
new notion of oligo-recurrence to overcome these 
problems. Oligo-recurrence is a notion similar to 
oligometastases, but oligo-recurrence was defined 
as the condition with a controlled primary lesion 
[4, 5]. In the states of oligometastases and oligo- 
-recurrence, patients with 1–2 metastases and re-
currences reportedly showed better prognosis than 
those with 3–5 metastases and recurrences [7]. 
When analyzing oligo-recurrence of NSCLC 
in only the brain or adrenal gland, patients achie-
ved favorable survival [6, 8]. In order to discover 
oligo-recurrence, positron emission tomography 
is considered to be essential. Also, MRI is consi-
dered essential in order to detect oligo-recurrence 
to the brain. In fact, in both patients of this report, 
oligo metastatic sites were found by PET/CT and 
brain MRI. The patient had no subjective symp-
toms at the time of lesion detection.
In patients with ALK rearranged NSCLC, 
the initiation of ALK-TKI is one of the treatment 
options when oligo-recurrence is found. If it can 
be treated with local therapy, however, there may 
be an option to withhold initiation of ALK-TKI and 
follow up the clinical course for a while. In fact, in 
case 1, ALK-TKI was not administered and followed 
up, but no recurrence was confirmed by PET/CT 
and brain MRI even 23 months after resection of 
the oligo-recurrence. In case 2, oligo-recurrence 
to the brain and left adrenal grand developed in 
the period of PEM + BEV maintenance therapy 
after additional postoperative treatment. After 
local therapy with stereotactic brain irradiation 
to the brain and adrenalectomy, therapy with cri-
zotinib was initiated. No recurrence was detected 
on PET/CT and brain MRI for 18 months after the 
local therapy. If ALK-TKI is administered, there 
is a high possibility of response, and long-term 
PFS will be obtained. However, the possibility of 
recurrence at any time remains high. Thus, in oli-
go-recurrence, the concept of using each effective 
treatment successfully over a long period of time 
may be important.
Control of the primary tumor, good nutritio-
nal status, less aggressive histological type and 
a small number of metastases are factors which 
impact the treatment of oligo-recurrence [4, 5, 
9, 10]. If local therapy is properly administered, 
oligo-recurrence allows for long-term control and 
avoids loss of quality of life. The detection of tiny 
oligo metastatic sites needs to be very carefully 
monitored, as oligo-recurrence may lead to long-
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-term survival. In view of the current technolo-
gical advances and the use of local and systemic 
treatments, surgery [4, 5, 9, 10] is appropriate for 
some patients with oligo-recurrence. Radiation 
therapy is the next best treatment. Stereotactic 
radiosurgery is an effective treatment, especially 
for oligo-recurrence to the brain.
In summary, among the patients with ALK 
rearranged NSCLC, it appears that some patients 
develop oligo-recurrence in their long clinical co-
urses. It is difficult to evaluate whether it is really 
oligo-recurrence. Regardless, for such patients, 
appropriate local therapy may be beneficial in 
improving the quality of life and prognosis. ALK 
rearranged NSCLC is a rare disease. In such rare 
diseases, information about oligo-recurrence 
is not available from clinical trials. Therefore, 
accumulating and sharing clinical experience is 
considered to be significant.
Conflict of interest
None declared.
References:
1. Griffin R, Ramirez RA. Molecular targets in non-small cell lung 
cancer. Ochsner J. 2017; 17(4): 388–392, indexed in Pubmed: 
29230123.
2. Vestergaard HH, Christensen MR, Lassen UN. A  sys-
tematic review of targeted agents for non-small cell 
lung cancer. Acta Oncol. 2018; 57(2): 176–186, doi: 
10.1080/0284186X.2017.1404634, indexed in Pubmed: 
29172833.
3. Weichselbaum RR, Hellman S. Oligometastases revisited. 
Nat Rev Clin Oncol. 2011; 8(6): 378–382, doi: 10.1038/nrcli-
nonc.2011.44, indexed in Pubmed: 21423255.
4. Niibe Y, Chang JY, Onishi H, et al. Oligometastases/Oligo-re-
currence of lung cancer. Pulm Med. 2013; 2013: 438236, doi: 
10.1155/2013/438236, indexed in Pubmed: 23476762.
5. Niibe Y, Hayakawa K. Oligometastases and oligo-recurrence: the 
new era of cancer therapy. Jpn J Clin Oncol. 2010; 40(2): 107–
111, doi: 10.1093/jjco/hyp167, indexed in Pubmed: 20047860.
6. Lopez Guerra JL, Gomez D, Zhuang Y, et al. Prognostic impact 
of radiation therapy to the primary tumor in patients with non
-small cell lung cancer and oligometastasis at diagnosis. Int J 
Radiat Oncol Biol Phys. 2012; 84(1): e61–e67, doi: 10.1016/j.
ijrobp.2012.02.054, indexed in Pubmed: 22503522.
7. Salama JK, Chmura SJ, Mehta N, et al. An initial report of 
a  radiation dose-escalation trial in patients with one to five 
sites of metastatic disease. Clin Cancer Res. 2008; 14(16): 
5255–5259, doi: 10.1158/1078-0432.CCR-08-0358, indexed in 
Pubmed: 18698045.
8. Holy R, Piroth M, Pinkawa M, et al. Stereotactic body radiation 
therapy (SBRT) for treatment of adrenal gland metastases from 
non-small cell lung cancer. Strahlenther Onkol. 2011; 187(4): 
245–251, doi: 10.1007/s00066-011-2192-z, indexed in Pubmed: 
21424513.
9. Jabbour SK, Daroui P, Moore D, et al. A  novel paradigm in 
the treatment of oligometastatic non-small cell lung can-
cer. J Thorac Dis. 2011; 3(1): 4–9, doi: 10.3978/j.issn.2072-
1439.2010.12.09, indexed in Pubmed: 22263057.
10. Bonnette P. [Non-small cell lung cancer with oligometasta-
ses: treatment with curative intent]. Cancer Radiother. 2012; 
16(5-6): 344–347, doi: 10.1016/j.canrad.2012.05.017, indexed 
in Pubmed: 22921976.
